{"id":209,"date":"2026-04-11T09:31:10","date_gmt":"2026-04-11T09:31:10","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=209"},"modified":"2026-09-30T09:04:44","modified_gmt":"2026-09-30T09:04:44","slug":"lucicaboz","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/fr\/product\/lucicaboz\/","title":{"rendered":"LuciCaboz"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciCaboz safely and effectively. See full prescribing information for LuciCaboz.<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciCaboz is a kinase inhibitor indicated for the treatment of <\/span><\/p>\n

\u2022 patients with advanced renal cell carcinoma (RCC) <\/span><\/p>\n

\u2022 patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab.<\/span><\/p>\n

\u2022 patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.<\/span><\/p>\n

\u2022 adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

\u2022 Stop treatment with LuciCaboz at least 3 weeks prior to scheduled surgery, including dental surgery.<\/span><\/p>\n

\u2022 Do NOT substitute LuciCaboz tablets with cabozantinib capsules.<\/span><\/p>\n

\u2022 Recommended Dose: <\/span><\/p>\n

\u2022 60 mg orally, once daily. <\/span><\/p>\n

\u2022 40 mg orally, once daily, in pediatric patients with BSA less than 1.2 m2<\/span><\/sup>.<\/span><\/p>\n

\u2022 40 mg orally, once daily, administered in combination with nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks.<\/span><\/p>\n

\u2022 Administer at least 1 hour before or at least 2 hours after eating.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 20 mg\u00d790 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

None.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Hemorrhage: Do not administer LuciCaboz if recent history of hemorrhage.<\/span><\/p>\n

\u2022 Perforations and Fistulas: Monitor for symptoms. Discontinue LuciCaboz for Grade 4 fistula or perforation. <\/span><\/p>\n

\u2022 Thrombotic Events: Discontinue LuciCaboz for myocardial infarction or serious venous or arterial thromboembolic events. <\/span><\/p>\n

\u2022 Hypertension and Hypertensive Crisis: Monitor blood pressure regularly. Interrupt for hypertension that is not adequately controlled with anti-hypertensive therapy. Discontinue LuciCaboz forhypertensive crisis or severe hypertension that cannot be controlled with anti-hypertensive therapy. <\/span><\/p>\n

\u2022 Diarrhea: May be severe. Interrupt LuciCaboz until diarrhea resolves or decreases to \u2264Grade 1, resume at reduced dose. Recommend standard antidiarrheal treatments. <\/span><\/p>\n

\u2022 Palmar-Plantar Erythrodysesthesia (PPE): Interrupt LuciCaboztreatment until PPE resolves or decreases to Grade 1. <\/span><\/p>\n

\u2022 Hepatotoxicity: When used in combination with nivolumab, higher frequencies of Grade 3 and 4 ALT and AST elevation may occur than with LuciCaboz alone. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider withholding LuciCaboz and\/or nivolumab, initiating corticosteroid therapy, and\/or permanently discontinuing the combination for severe or lifethreatening hepatotoxicity.<\/span><\/p>\n

\u2022 Adrenal Insufficiency: When used in combination with nivolumab, primary or secondary adrenal insufficiency may occur. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold LuciCaboz and\/or nivolumab depending on severity. <\/span><\/p>\n

\u2022 Proteinuria: Monitor urine protein. Interrupt LuciCaboz until proteinuria resolves to \u2264 Grade 1, resume LuciCaboz at a reduced dose. Discontinue for nephrotic syndrome. <\/span><\/p>\n

\u2022 Osteonecrosis of the jaw (ONJ): Withhold LuciCaboz for at least 3 weeks prior to invasive dental procedures and for development of ONJ.<\/span><\/p>\n

\u2022 Impaired Wound Healing: Withhold LuciCaboz for at least 3 weeks before elective surgery. Do not administer for at least 2 weeks following major surgery and adequate wound healing. The safety of resumption of LuciCaboz after resolution of wound healing complications has not <\/span><\/p>\n

been established. <\/span><\/p>\n

\u2022 Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue LuciCaboz. <\/span><\/p>\n

\u2022 Thyroid Dysfunction: Monitor thyroid function before and during treatment with LuciCaboz. <\/span><\/p>\n

\u2022 Hypocalcemia: Withhold LuciCaboz and resume at reduced dose upon recovery or permanently discontinue LuciCaboz depending on severity.<\/span><\/p>\n

\u2022 Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. <\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

The most common (\u2265 20%) adverse reactions are: <\/span><\/p>\n

\u2022 as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, constipation.<\/span><\/p>\n

\u2022 in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. <\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Strong CYP3A4 inhibitors: Reduce the LuciCaboz dosage if coadministration cannot be avoided. <\/span><\/p>\n

\u2022 Strong CYP3A4 inducers: Increase the LuciCaboz dosage if coadministration cannot be avoided. <\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Hepatic Impairment: Reduce the LuciCaboz dosage for patients with moderate hepatic impairment. Avoid in patients with severe hepatic impairment. <\/span><\/p>\n

\u2022 Lactation: Advise not to breastfeed. <\/span><\/p>\n

\u2022 Pediatric Use: Monitor open growth plates in adolescent patients. Consider interrupting or discontinuing LuciCaboz if abnormalities occur. <\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u2103 to 25\u2103 (68\u2109 to 77\u2109), excursions permitted between 15\u2103 and 30\u2103 (59\u2109 and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciCaboz contains cabozantinib and is supplied as oral tablets. Please confirm the prescribed strength and review the full product information before ordering. A valid prescription and identity verification are required.<\/p>","protected":false},"featured_media":2126,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[49],"product_tag":[],"class_list":["post-209","product","type-product","status-publish","has-post-thumbnail","product_cat-kidney-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product\/209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/comments?post=209"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media\/2126"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media?parent=209"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_brand?post=209"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_cat?post=209"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_tag?post=209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}